KR20040084905A - 2-옥사졸아민 및 5-ｈｔ2ｂ 수용체 길항물질로서의 그 용도 - Google Patents

2-옥사졸아민 및 5-ｈｔ2ｂ 수용체 길항물질로서의 그 용도 Download PDF

Info

Publication number
KR20040084905A
KR20040084905A KR10-2004-7012479A KR20047012479A KR20040084905A KR 20040084905 A KR20040084905 A KR 20040084905A KR 20047012479 A KR20047012479 A KR 20047012479A KR 20040084905 A KR20040084905 A KR 20040084905A
Authority
KR
South Korea
Prior art keywords
alkyl
naphthalen
optionally substituted
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7012479A
Other languages
English (en)
Korean (ko)
Inventor
옥스포드앨리그잰더윌리엄
보먼리차드앤소니
콜먼로버트앨리그잰더
클라크케네스라일
하인드조지
아처재닛앤
알리아만다
해리스닐빅터
Original Assignee
파마겐 래보레토리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마겐 래보레토리즈 리미티드 filed Critical 파마겐 래보레토리즈 리미티드
Publication of KR20040084905A publication Critical patent/KR20040084905A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2004-7012479A 2002-02-13 2003-02-11 2-옥사졸아민 및 5-ｈｔ2ｂ 수용체 길항물질로서의 그 용도 Ceased KR20040084905A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203412.2 2002-02-13
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists
PCT/GB2003/000552 WO2003068226A1 (en) 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-ht2b receptor antagonists

Publications (1)

Publication Number Publication Date
KR20040084905A true KR20040084905A (ko) 2004-10-06

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7012479A Ceased KR20040084905A (ko) 2002-02-13 2003-02-11 2-옥사졸아민 및 5-ｈｔ2ｂ 수용체 길항물질로서의 그 용도

Country Status (17)

Country Link
US (1) US7429607B2 (https=)
EP (1) EP1474140B1 (https=)
JP (1) JP4439266B2 (https=)
KR (1) KR20040084905A (https=)
CN (1) CN1633291A (https=)
AU (1) AU2003207297B2 (https=)
CA (1) CA2472762A1 (https=)
DE (1) DE60317632T2 (https=)
EA (1) EA200401077A1 (https=)
GB (1) GB0203412D0 (https=)
IL (1) IL163110A (https=)
MX (1) MXPA04007738A (https=)
NO (1) NO327465B1 (https=)
NZ (1) NZ534539A (https=)
PL (1) PL370221A1 (https=)
WO (1) WO2003068226A1 (https=)
ZA (1) ZA200406010B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299948B1 (it) 1998-04-02 2000-04-04 Azionaria Costruzioni Acma Spa Metodo e dispositivo per la formazione di gruppi di articoli appiattiti.
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
WO2005012263A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
JPWO2005079845A1 (ja) 2004-02-20 2007-08-02 アステラス製薬株式会社 片頭痛予防薬
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
DK1797038T3 (da) 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
US9464062B2 (en) 2012-11-28 2016-10-11 Temple University—Of the Commonwealth System of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트
CN116789549A (zh) * 2023-06-16 2023-09-22 山东科源化工有限公司 一种羟基乙酸乙烯酯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
AU679635B2 (en) 1994-03-11 1997-07-03 Eli Lilly And Company Method for treating 5HT-2B receptor related conditions
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ATE227710T1 (de) * 1996-04-03 2002-11-15 Takeda Chemical Industries Ltd Oxazole derivate,ihre herstellung und verwendung
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
JP2004500333A (ja) 1999-07-30 2004-01-08 ファーマジーン　ラボラトリーズ　リミテッド 胃腸管障害の治療における、２−アミノ−４−（４−フルオロナフタ−１−イル）−６−イソプロピルピリミジンの使用
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Also Published As

Publication number Publication date
NO20043799L (no) 2004-09-10
CA2472762A1 (en) 2003-08-21
EP1474140A1 (en) 2004-11-10
ZA200406010B (en) 2005-06-08
AU2003207297A1 (en) 2003-09-04
JP4439266B2 (ja) 2010-03-24
GB0203412D0 (en) 2002-04-03
WO2003068226A1 (en) 2003-08-21
DE60317632T2 (de) 2008-10-30
NZ534539A (en) 2006-02-24
NO327465B1 (no) 2009-07-06
PL370221A1 (en) 2005-05-16
DE60317632D1 (de) 2008-01-03
JP2005528341A (ja) 2005-09-22
CN1633291A (zh) 2005-06-29
EA200401077A1 (ru) 2005-06-30
IL163110A (en) 2010-12-30
MXPA04007738A (es) 2004-10-15
EP1474140B1 (en) 2007-11-21
AU2003207297A2 (en) 2003-09-04
US20040010022A1 (en) 2004-01-15
AU2003207297B2 (en) 2008-11-06
US7429607B2 (en) 2008-09-30

Similar Documents

Publication Publication Date Title
JP4061332B2 (ja) 新規チアゾリジン−４−オン誘導体
EP0699192B1 (en) Substituted oxazolyl compounds for the treatment of inflammation
RS50606B (sr) Supstituisani morfolin i tiomorfolin derivati
JP2009544620A (ja) 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト
HU228960B1 (hu) Ftalazinon-származékok
MX2007010401A (es) Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
CN107082770A (zh) IRE‑1α抑制剂
KR20010079952A (ko) 인데노-, 나프토- 및 벤조사이클로헵타 디하이드로티아졸유도체, 이의 제조방법 및 식욕감퇴제로서의 이의 용도
JP2006528617A (ja) ５−ｈｔ２ｂ受容体アンタゴニスト
NO332420B1 (no) EP4 reseptor antagonister, andvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse
JP2006524687A (ja) バニロイド受容体で阻害活性を示す新規複素環アミド
SK164598A3 (en) 5-phenoxyalkyl-2,4-thiazolidinedione derivative, method for the preparaton thereof, intermediate products for its preparation and pharmaceutical composition containing same
KR20080034436A (ko) 암 치료에 사용되는 티아졸 유도체 및 유사체
KR20040084905A (ko) 2-옥사졸아민 및 5-ｈｔ2ｂ 수용체 길항물질로서의 그 용도
KR960012206B1 (ko) 티아졸리딘-2,4-디온 유도체 및 이의 염, 이의 제조방법 및 이의 용도
JP2008512438A (ja) 療法用ジフェニルエーテル系リガンド
KR20080003380A (ko) 우레아 유도체들, 그 제조방법 및 그 이용
JPH08500101A (ja) 炎症抑制剤として有用な２−複素環−５−ヒドロキシ−１，３−ピリミジン類
JP2005526720A (ja) ５−ｈｔ２ｂ受容体アンタゴニスト
US20050176791A1 (en) 5-HT2B receptor antagonists
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
CN101262864A (zh) 饱和o-杂环取代的烷酰胺
WO2005097113A2 (en) 5-ht2b receptor antagonists
MXPA06010329A (en) Substituted morpholine and thiomorpholine derivatives
JPH0469385A (ja) 新規イミダゾリン誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080205

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091224

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100603

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20091224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I